France · Delayed Price · Currency is EUR MaaT Pharma Earnings Call Transcripts
Fiscal Year 2025
-
A transformative exclusive partnership with Clinigen will drive Xervyteg’s commercialization across Europe, supported by strong early access data and a robust financial agreement. Manufacturing is ready for scale, and the deal extends cash runway into 2026, setting a benchmark for future growth and expansion.
-
The ARES phase 3 trial of MaaT013 in severe, refractory acute GVHD demonstrated a 62% GI response rate at day 28 and a 54% one-year survival, far surpassing historical outcomes. Regulatory submission in Europe is imminent, with commercialization and expansion plans supported by strong safety, robust real-world data, and a EUR 750 million market opportunity.
Fiscal Year 2024
-
KOLs highlighted the high unmet need in acute GVHD, with MaaT013 showing strong response and survival rates in heavily pretreated patients, especially those refractory to ruxolitinib. Upcoming phase 3 results in January 2025 are expected to be pivotal for approval and expansion.